Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib, Temsirolimus, and Cyclophosphamide in Advanced Solid Tumors
NCT02389309Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2015
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib, temsirolimus and cyclophosphamide in solid tumor and brain neoplasm, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 35 days, Dose-Limiting Toxicities at 35 days and 1 more. Started Oct 2015; status: active, not recruiting.
02
Drugs
dasatinibtemsirolimuscyclophosphamide
03
Conditions
solid tumorbrain neoplasm
Beyond the preview
Go deeper on NCT02389309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389309.